(0.01%) 5 479.25 points
(0.01%) 38 821 points
(0.04%) 19 930 points
(0.30%) $80.57
(0.65%) $2.81
(0.13%) $2 332.00
(-0.31%) $29.30
(-0.05%) $970.40
(0.02%) $0.932
(-0.14%) $10.64
(0.07%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics...
Stats | |
---|---|
Šios dienos apimtis | 2 908 |
Vidutinė apimtis | 733 125 |
Rinkos kapitalizacija | 2.84B |
EPS | $-0.530 ( Q1 | 2024-05-07 ) |
Kita pelno data | ( $-0.560 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-18.75 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0520 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-31 | Rosen Terry J | Buy | 16 200 | Stock Option (right to buy) |
2024-05-31 | Kelley Susan L. | Buy | 16 200 | Stock Option (right to buy) |
2024-05-31 | Hampton Malcolm Garret | Buy | 16 200 | Stock Option (right to buy) |
2024-05-31 | Stein Jeffrey | Buy | 16 200 | Stock Option (right to buy) |
2024-05-31 | Morrison Scott W | Buy | 16 200 | Stock Option (right to buy) |
INSIDER POWER |
---|
21.42 |
Last 100 transactions |
Buy: 1 731 485 | Sell: 1 162 652 |
Tūris Koreliacija
IDEAYA Biosciences Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
MREO | 0.887 |
CPLP | 0.874 |
CFBK | 0.865 |
RBKB | 0.841 |
AVIR | 0.828 |
BHFAP | 0.827 |
BHFAO | 0.819 |
VSTM | 0.817 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
IDEAYA Biosciences Inc Koreliacija - Valiuta/Žaliavos
IDEAYA Biosciences Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $23.39M |
Bruto pelnas: | $19.38M (82.86 %) |
EPS: | $-1.960 |
FY | 2023 |
Pajamos: | $23.39M |
Bruto pelnas: | $19.38M (82.86 %) |
EPS: | $-1.960 |
FY | 2022 |
Pajamos: | $50.93M |
Bruto pelnas: | $48.83M (95.87 %) |
EPS: | $-1.320 |
FY | 2021 |
Pajamos: | $27.94M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.410 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
IDEAYA Biosciences Inc
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.